| Intrinsic Valuation of: TORNTPHARM | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 67 | Market Cap | ₹1,491B | |||||
| 2021 | - | - (-) | P/E Ratio | 66 | Total Asset | ₹150B | |||||
| 2022 | ₹16B | - (-) | Net Income | ₹19B | Total Debt | ₹12B | |||||
| 2023 | ₹18B | 12.1% (-0.3%) | EBITDA | ₹37B | Total Liab | ₹74B | |||||
| 2024 | ₹28B | 57.9% (41.5%) | Opr Margin | 25.85 | Debt/Equity | 0.16 | |||||
| 2025 | ₹20B | -30.4% (-35.0%) | PreTax Margin | 23.63 | BV/Share | 88 | |||||
| 5Y Average FCF | ₹21B | 11.5% (2.1%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.01% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (11.5%) | ||||||||||
| 2026 | ₹22B | MBG Intrinsic Value | ₹599 | ||||||||
| 2027 | ₹24B | ||||||||||
| 2028 | ₹26B | ||||||||||
| 2029 | ₹28B | ||||||||||
| 2030 | ₹29B | ||||||||||
| 2031 | ₹30B | ||||||||||
| Terminal Value | ₹676B | Net Worth/Share | ₹224 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹576B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹6B | ₹1,682 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹12B | WACC | 6.5% | 1,583 | 1,725 | 1,902 | 2,130 | 2,433 | |||
| Equity Value | ₹569B | 7.1% | 1,401 | 1,508 | 1,639 | 1,801 | 2,008 | ||||
| Shares Outstanding | 338,445,440 | 7.8% | 1,255 | 1,339 | 1,439 | 1,559 | 1,708 | ||||
| 8.4% | 1,138 | 1,205 | 1,283 | 1,376 | 1,488 | ||||||
| DCF Intrinsic Value | ₹1,682 | 9.0% | 1,039 | 1,093 | 1,156 | 1,229 | 1,315 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||